Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

NCT05077813 is registered in ClinicalTrials.gov with Kafrelsheikh University as lead sponsor.

NCT NCT05077813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19
Lead sponsor
Kafrelsheikh University
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2021
Completion date
February 28, 2022
Enrollment
250 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis